Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys:: Relationship to anticataleptic effect

被引:18
|
作者
Milhara, Takuma [1 ]
Noda, Akihiro [2 ]
Arai, Hiroshi [3 ]
Mihara, Kayoko [1 ]
Iwashita, Akinori [1 ]
Murakami, Yoshihiro [2 ]
Matsuya, Takahiro [2 ]
Miyoshi, Sosuke [2 ]
Nishimura, Shintaro [2 ]
Matsuoka, Nobuya [1 ]
机构
[1] Astellas Pharma Inc, Pharmacol Res Labs, Tsukuba, Ibaraki 3058585, Japan
[2] Astellas Pharma Inc, Appl Pharmacol Res Labs, Tsukuba, Ibaraki 3058585, Japan
[3] Astellas Pharma Inc, Drug Metab Res Labs, Tokyo, Japan
关键词
PET; ASP5854; C-11-SCH442416; catalepsy; adenosine A(2A) receptors;
D O I
10.2967/jnumed.108.051474
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The purpose of the present study was to measure adenosine A(2A) receptor (A(2A)R) occupancy in the brain by a novel adenosine A(1)/A(2A) antagonist, 5-[5-amino-3-(4fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), and to determine the degree of receptor occupancy necessary to inhibit haloperidol-induced catalepsy in rhesus monkeys. Methods: A(2A)R occupancy by ASP5854 (0.001-0.1 mg/kg) was examined in the striatum using an A(2A)R-specific radiotracer, C-11-SCH442416, and PET in conscious rhesus monkeys. A(2A)R occupancy was monitored after a single intravenous administration of ASP5854 in 3 animals, and a dynamic PET scan was performed at 1, 4, and 8 h after an intravenous bolus injection of the tracer for approximately 740 MBq. Catalepsy was induced by haloperidol (0.03 mg/kg, intramuscularly) and examined for incidence and duration. Results: ASP5854 dose-dependently increased A2AR occupancy in the striatum and showed long-lasting occupancy even after the reduction of plasma concentration. Haloperidol induced severe catalepsy at 40 min after intramuscular injection. The incidence and duration of cataleptic posture were dose-dependently reduced by ASP5854 at 1 h after oral administration, and the minimum ED50 value was 0.1 mg/kg. Administration of a dose of 0.1 mg/kg yielded a plasma concentration of 97 +/- 16.3 ng/mL, which corresponded to 85%-90% of A(2A)R occupancy. Conclusion: These results showed that ASP5854 antagonized A(2A)R in the striatum, and the dissociation from A(2A)R was relatively slow. In addition, more than 85% A(2A)R occupancy by ASP5854 resulted in an inhibition of haloperidol-induced catalepsy. Thus, such a pharmacodynamic study directly demonstrates both the kinetics of a drug in the brain and the relationship between dose-dependent receptor occupancy and plasma level.
引用
收藏
页码:1183 / 1188
页数:6
相关论文
共 50 条
  • [1] ASP5854, a novel adenosine A1 & A2A receptor antagonist, improves cognitive impairment, anxiety and depression in animal models
    Mihara, Takuma
    Mihara, Kayoko
    Yarimizu, Junko
    Matsuda, Ritsuko
    Aota, Masaki
    Twashita, Akinori
    Matsuoka, Nobuya
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2008, 106 : 181P - 181P
  • [2] ASP5854, a novel potent adenosine A1 & A2A receptor dual antagonist, improves motor disabilities and neuronal degeneration in models of Parkinson's disease
    Mihara, Kayoko
    Mihara, Takuma
    Mitani, Yasuyiki
    Matsuda, Ritsuko
    Yamamoto, Hiroko
    Aoki, Satoshi
    Akahane, Atsushi
    Iwashita, Akinori
    Matsuoka, Nobuya
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2008, 106 : 181P - 181P
  • [3] A novel adenosine A1 and A2A receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: Comparison with existing anti-Parkinson's disease drugs
    Mihara, Takuma
    Iwashita, Akinori
    Matsuoka, Nobuya
    BEHAVIOURAL BRAIN RESEARCH, 2008, 194 (02) : 152 - 161
  • [4] Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade
    Cunha R.A.
    Purinergic Signalling, 2005, 1 (2) : 111 - 134
  • [5] ZM 241385, an adenosine A2A receptor antagonist, inhibits hippocampal A1 receptor responses
    Lopes, LV
    Cunha, RA
    Ribeiro, JA
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 383 (03) : 395 - 398
  • [6] Quinolinedione nucleus as a novel scaffold for A1 and A2A adenosine receptor antagonists
    Mosti, Luisa
    Fossa, Paola
    Menozzi, Giulia
    Trincavelli, Letizia
    Floreani, Maura
    MEDICINAL CHEMISTRY RESEARCH, 2008, 17 (09) : 587 - 603
  • [7] Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys:: Effect on adenosine A2A receptors
    Morissette, Marc
    Dridi, Mehdi
    Calon, Frederic
    Tahar, Abdallah Hadj
    Meltzer, Leonard T.
    Bedard, Paul J.
    Di Paolo, Therese
    SYNAPSE, 2006, 60 (03) : 239 - 250
  • [8] Quinolinedione nucleus as a novel scaffold for A1 and A2A adenosine receptor antagonists
    Luisa Mosti
    Paola Fossa
    Giulia Menozzi
    Letizia Trincavelli
    Maura Floreani
    Medicinal Chemistry Research, 2008, 17 : 587 - 603
  • [9] Adenosine receptor modelling.: A1/A2a selectivity
    Tuccinardi, T
    Ortore, G
    Manera, C
    Saccomanni, G
    Martinelli, A
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2006, 41 (03) : 321 - 329
  • [10] A covalent antagonist for the human adenosine A2A receptor
    Yang, Xue
    Dong, Guo
    Michiels, Thomas J. M.
    Lenselink, Eelke B.
    Heitman, Laura
    Louvel, Julien
    IJzerman, Ad P.
    PURINERGIC SIGNALLING, 2017, 13 (02) : 191 - 201